Small cell lung cancer: an overview of the targets

Valadares, Bruna Nardy; Stephano, Marco Antônio

doi:10.1590/s2175-97902022e19114

Cited by 2 publications

(3 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings, indicating a median PFS of 5.0 months and OS of 13.0 months, underscore the potential of this combination therapy. These survival rates, coupled with a high DCR and ORR, are promising, especially considering the aggressive nature and traditionally poor prognosis associated with ES-SCLC 29 , 30 . The primary adverse event observed, hypertension, is a known effect of antiangiogenic therapies and aligns with findings from other studies in lung cancer treatments 31 , 32 .…”

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

Lv,

Liu,

Feng

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Background: The primary aim of this phase II clinical study was to assess the safety and efficacy of combining anlotinib, etoposide, and platinum-based drugs as a first-line treatment for ES-SCLC. Methods: Patients underwent the standard chemotherapeutic regimen, consisting of four courses of etoposide plus cisplatin/carboplatin. Additionally, each patient received a 2-week intervention with anlotinib (12 mg/day, once daily). Anlotinib was continued until disease progression, occurrence of unbearable adverse events (AEs), or withdrawal from the research. Progression-free survival (PFS) served as the primary prognostic measure. Secondary measures included the disease control rate (DCR), objective response rate (ORR), overall survival time (OS), and the incidence of AEs. Results: The DCR and ORR were 97.6% and 91.0%, respectively. Estimated PFS and OS were 5.0 months (95% CI: 1.0-10.8 months) and 13.0 months (95% CI: 8.4-18.6 months), respectively. No unexpected adverse effects were reported during the trial. The most common adverse reactions included anemia (42.22%), hypertension (53.33%), alopecia (40.00%), elevated transaminase (24.40%), and elevated alkaline phosphatase (24.44%). Sixteen cases (35.56%) were classified as AEs of grades 3-5. No deaths attributed to treatment-related causes occurred in any patient during the trial. Conclusion: Combination chemotherapy is currently the first-line therapy for extensive small-cell lung cancer (ES-SCLC). Combining anlotinib with conventional platinum-based chemotherapy demonstrated promising therapeutic outcomes and prognosis in the management of ES-SCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

Lv,

Liu,

Feng

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Depending on the location of primary lesions, lung cancers could be divided into central and peripheral types. The central type of lung cancer is mostly squamous-cell carcinoma and SCLC, while the peripheral type is mainly ADC (4)(5)(6). Peripheral SCLC (PSCLC) is relatively less common in clinical practice, accounting for 15-30% of all lung cancers (6,7).…”

Section: Introductionmentioning

confidence: 99%

“…The central type of lung cancer is mostly squamous-cell carcinoma and SCLC, while the peripheral type is mainly ADC (4)(5)(6). Peripheral SCLC (PSCLC) is relatively less common in clinical practice, accounting for 15-30% of all lung cancers (6,7). PSCLC typically originates in the bronchial submucosa and infiltrates into the peribronchial connective tissue, resulting in bronchial stenosis being less likely to occur in its early stage.…”

Section: Introductionmentioning

confidence: 99%

CT radiomics model combined with clinical and radiographic features for discriminating peripheral small cell lung cancer from peripheral lung adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

PurposeExploring a non-invasive method to accurately differentiate peripheral small cell lung cancer (PSCLC) and peripheral lung adenocarcinoma (PADC) could improve clinical decision-making and prognosis.MethodsThis retrospective study reviewed the clinicopathological and imaging data of lung cancer patients between October 2017 and March 2022. A total of 240 patients were enrolled in this study, including 80 cases diagnosed with PSCLC and 160 with PADC. All patients were randomized in a seven-to-three ratio into the training and validation datasets (170 vs. 70, respectively). The least absolute shrinkage and selection operator regression was employed to generate radiomics features and univariate analysis, followed by multivariate logistic regression to select significant clinical and radiographic factors to generate four models: clinical, radiomics, clinical-radiographic, and clinical-radiographic-radiomics (comprehensive). The Delong test was to compare areas under the receiver operating characteristic curves (AUCs) in the models.ResultsFive clinical-radiographic features and twenty-three selected radiomics features differed significantly in the identification of PSCLC and PADC. The clinical, radiomics, clinical-radiographic and comprehensive models demonstrated AUCs of 0.8960, 0.8356, 0.9396, and 0.9671 in the validation set, with the comprehensive model having better discernment than the clinical model (P=0.036), the radiomics model (P=0.006) and the clinical–radiographic model (P=0.049).ConclusionsThe proposed model combining clinical data, radiographic characteristics and radiomics features could accurately distinguish PSCLC from PADC, thus providing a potential non-invasive method to help clinicians improve treatment decisions.

show abstract

Small cell lung cancer: an overview of the targets

Cited by 2 publications

References 77 publications

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

CT radiomics model combined with clinical and radiographic features for discriminating peripheral small cell lung cancer from peripheral lung adenocarcinoma

Contact Info

Product

Resources

About